The management of inflammatory bowel disease represents a key component of clinical
practice for members of the British Society of Gastroenterology (BSG). There has been …

Recent studies have identified mucosal healing on endoscopy as a key prognostic
parameter in the management of inflammatory bowel diseases (IBD), thus highlighting the …

When deciding the appropriate treatment strategy for active ulcerative colitis one should
consider the activity, distribution (proctitis, left-sided, extensive 1), and pattern of disease …

BACKGROUND & AIMS: Adalimumab is a fully human monoclonal antibody that binds tumor
necrosis factor (TNF)-α. Its efficacy as maintenance therapy for patients with ulcerative colitis …

Objective The aim of this study was to assess the efficacy and safety of adalimumab (ADA), a
recombinant human monoclonal antibody against tumour necrosis factor α (TNF), for the …

Background One‐third of patients with Crohn's disease (CD) or ulcerative colitis (UC)
receiving anti‐TNF s do not respond to treatment, and a relevant proportion experience loss …

Background & Aims Ustekinumab, an inhibitor of the p40 subunit of interleukins 12 and 23,
is an effective treatment for patients with Crohn's disease (CD). Trough concentrations of …

Mucosal healing (MH) has emerged as an important treatment goal for patients with IBD.
Historically, the therapeutic goals of induction and maintenance of clinical remission …

Background and Aims: Interleukin 17 (IL17) is now known to be involved in a number of
chronic inflammatory disorders. However, the mechanisms regulating its production in …

Intestinal barrier dysfunction is a main feature of the inflammatory bowel diseases (IBD),
Crohn's disease and ulcerative colitis. Leak flux diarrhoea and a facilitated uptake of …